Other languages PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
25.21 ^USD	-0.67%		+0.20%	-8.53%

Mar. 28	PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	MT
Mar. 28	PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	Mar. 28
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	Mar. 28
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	Mar. 19
PTC Therapeutics Shares Jump Following Q4 Results	Mar. 01
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	Feb. 29
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26
Sector Update: Health Care Stocks Mixed Premarket Friday	Jan. 26
Sector Update: Health Care	Jan. 26
PTC Therapeutics' Muscle Disorder Drug Gets Negative Opinion From European Medicines Agency	Jan. 25
Europe to withdraw PTC Therapeutics' rare muscle disorder drug	Jan. 25
PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing	Jan. 25
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn Following Re-examination Procedure	Jan. 25
Ptc Therapeutics Insider Sold Shares Worth $273,804, According to a Recent SEC Filing	Jan. 24
PTC Therapeutics Shares Rise as Preliminary 2023 Revenue Tops Consensus	Jan. 08
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024	Jan. 08
PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities	Dec. 05
Sector Update: Health Care Stocks Slip in Late Afternoon	23-10-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Other languages

Filters